Figure 4

Comparison of clinical parameters [Median, 95% CrI], luteal support regimens duration and dosage across treatment groups. Progesterone levels on hCG trigger day (ng/ml) (A), Progesterone levels on embryo transfer (ET) day (ng/ml) (B), Endometrial thickness measurement on ET day (C), Ovarian stimulation protocol employed (D). Only comparisons that reached statistical significance are depicted. The reference group was PVP. Two decimal p values and asterisk annotation of significance where p-value < 0.05, it is flagged with one star (*), p-value < 0.01, 2 stars (**), p-value < 0.001, three stars (***), p-value < 0.0001, four stars (****). Abbreviations: LPS (luteal support), hCG (Human chorionic gonadotropin), hMG (human menopausal gonadotrophin), placebo (no exposure), SCP (Subcutaneous progesterone), VP (vaginal progesterone), IMP + VP (intramuscular progesterone and vaginal progesterone), VP + OE (vaginal progesterone and oral estradiol), IMP (intramuscular progesterone), VP + PatchE (vaginal progesterone and patch oestrogen), IMP + OE (intramuscular progesterone and oral estradiol), IMHCG (intramuscular hCG), SCP + VP, Intranasal GnRH-a, OP (oral progesterone), IMP + IME (intramuscular progesterone and intramuscular estradiol), IMP + VP + OE (Intramuscular progesterone, vaginal progesterone and oral estradiol), IMP + VE (Intramuscular progesterone and vaginal estradiol), VP + SCGNRH-a [(Vaginal progesterone and subcutaneous GNRH agonist (GNRH-a)], VP + OE + SCGNRH-a (Vaginal progesterone, oral estradiol and subcutaneous GNRH-a), RP (Rectal progesterone), SCHCG (subcutaneous HCG), VP + DHEA (vaginal progesterone and oral DHEA), IMP + VP + SCGNRH-a (Intramuscular progesterone, vaginal progesterone and subcutaneous GNRH-a), OP + VP (oral progesterone and vaginal progesterone).